End-of-day quote
Korea S.E.
06:00:00 2024-05-02 pm EDT
|
5-day change
|
1st Jan Change
|
8,790
KRW
|
-0.11%
|
|
-0.23%
|
-16.44%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
141,469
|
119,395
|
156,395
|
167,123
|
227,536
|
118,793
|
Enterprise Value (EV)
1 |
170,700
|
246,923
|
269,921
|
290,383
|
409,242
|
361,257
|
P/E ratio
|
-36.2
x
|
-5.35
x
|
-8.15
x
|
-2.36
x
|
-2.11
x
|
-1.99
x
|
Yield
|
1.52%
|
0.9%
|
0.72%
|
0.68%
|
0.5%
|
0.95%
|
Capitalization / Revenue
|
3.01
x
|
0.41
x
|
0.26
x
|
0.28
x
|
0.34
x
|
0.19
x
|
EV / Revenue
|
3.63
x
|
0.84
x
|
0.45
x
|
0.49
x
|
0.61
x
|
0.57
x
|
EV / EBITDA
|
64.1
x
|
-50.5
x
|
9.73
x
|
-6.97
x
|
-6.96
x
|
-8.68
x
|
EV / FCF
|
109
x
|
-5.18
x
|
24.8
x
|
3.08
x
|
-2.98
x
|
-8.78
x
|
FCF Yield
|
0.92%
|
-19.3%
|
4.04%
|
32.5%
|
-33.6%
|
-11.4%
|
Price to Book
|
0.82
x
|
0.87
x
|
1.27
x
|
3.13
x
|
19.3
x
|
3.05
x
|
Nbr of stocks (in thousands)
|
11,296
|
11,294
|
11,292
|
11,292
|
11,292
|
11,292
|
Reference price
2 |
12,524
|
10,571
|
13,850
|
14,800
|
20,150
|
10,520
|
Announcement Date
|
3/14/19
|
3/12/20
|
3/18/21
|
3/17/22
|
3/16/23
|
3/14/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
47,050
|
292,221
|
596,469
|
592,375
|
675,540
|
638,448
|
EBITDA
1 |
2,664
|
-4,888
|
27,752
|
-41,660
|
-58,832
|
-41,608
|
EBIT
1 |
-267
|
-25,871
|
-10,493
|
-81,732
|
-98,263
|
-79,553
|
Operating Margin
|
-0.57%
|
-8.85%
|
-1.76%
|
-13.8%
|
-14.55%
|
-12.46%
|
Earnings before Tax (EBT)
1 |
-2,944
|
-47,273
|
-28,408
|
-176,529
|
-172,950
|
-132,077
|
Net income
1 |
-3,719
|
-22,459
|
-19,185
|
-70,891
|
-102,353
|
-59,587
|
Net margin
|
-7.91%
|
-7.69%
|
-3.22%
|
-11.97%
|
-15.15%
|
-9.33%
|
EPS
2 |
-345.7
|
-1,975
|
-1,699
|
-6,278
|
-9,555
|
-5,277
|
Free Cash Flow
1 |
1,566
|
-47,672
|
10,896
|
94,273
|
-137,411
|
-41,144
|
FCF margin
|
3.33%
|
-16.31%
|
1.83%
|
15.91%
|
-20.34%
|
-6.44%
|
FCF Conversion (EBITDA)
|
58.76%
|
-
|
39.26%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
190.5
|
95.24
|
100.0
|
100.0
|
100.0
|
100.0
|
Announcement Date
|
3/14/19
|
3/12/20
|
3/18/21
|
3/17/22
|
3/16/23
|
3/14/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
29,230
|
127,528
|
113,526
|
123,260
|
181,706
|
242,464
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
10.97
x
|
-26.09
x
|
4.091
x
|
-2.959
x
|
-3.089
x
|
-5.827
x
|
Free Cash Flow
1 |
1,566
|
-47,672
|
10,896
|
94,273
|
-137,411
|
-41,144
|
ROE (net income / shareholders' equity)
|
-2.26%
|
-16.4%
|
-9.65%
|
-50.2%
|
-93.7%
|
-58%
|
ROA (Net income/ Total Assets)
|
-0.06%
|
-3.02%
|
-0.82%
|
-5.9%
|
-6.89%
|
-5.72%
|
Assets
1 |
6,018,391
|
743,883
|
2,354,033
|
1,201,658
|
1,486,043
|
1,042,383
|
Book Value Per Share
2 |
15,221
|
12,183
|
10,867
|
4,723
|
1,046
|
3,450
|
Cash Flow per Share
2 |
3,128
|
9,247
|
11,115
|
15,466
|
8,767
|
6,304
|
Capex
1 |
3,141
|
9,364
|
18,142
|
17,153
|
12,698
|
13,487
|
Capex / Sales
|
6.68%
|
3.2%
|
3.04%
|
2.9%
|
1.88%
|
2.11%
|
Announcement Date
|
3/14/19
|
3/12/20
|
3/18/21
|
3/17/22
|
3/16/23
|
3/14/24
|
|
1st Jan change
|
Capi.
|
---|
| -16.44% | 73.15M | | +31.52% | 690B | | +24.05% | 546B | | -5.21% | 358B | | +17.02% | 323B | | +5.01% | 287B | | +13.55% | 235B | | +4.32% | 199B | | -10.27% | 195B | | +3.98% | 161B |
Other Pharmaceuticals
|